E Fund Management Co. Ltd. Has $415,000 Stock Position in Novavax, Inc. (NASDAQ:NVAX)

E Fund Management Co. Ltd. lifted its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 69.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 86,558 shares of the biopharmaceutical company’s stock after buying an additional 35,581 shares during the period. E Fund Management Co. Ltd.’s holdings in Novavax were worth $415,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of NVAX. Commonwealth Equity Services LLC grew its position in Novavax by 14.6% during the 3rd quarter. Commonwealth Equity Services LLC now owns 17,307 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 2,201 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Novavax during the 3rd quarter valued at about $212,000. Raymond James & Associates bought a new stake in shares of Novavax during the 3rd quarter valued at about $1,021,000. Raymond James Financial Services Advisors Inc. bought a new stake in shares of Novavax during the 3rd quarter valued at about $76,000. Finally, Bank of New York Mellon Corp raised its stake in Novavax by 3.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 364,532 shares of the biopharmaceutical company’s stock worth $2,639,000 after buying an additional 13,326 shares during the period. Institutional investors own 53.04% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright dropped their price target on Novavax from $35.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, March 1st.

Novavax Price Performance

NASDAQ NVAX remained flat at $4.47 on Thursday. The company’s stock had a trading volume of 4,454,522 shares, compared to its average volume of 7,090,978. The stock’s 50 day simple moving average is $4.67 and its two-hundred day simple moving average is $4.99. Novavax, Inc. has a 1-year low of $3.53 and a 1-year high of $10.30. The company has a market cap of $627.60 million, a price-to-earnings ratio of -0.82 and a beta of 1.63.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.95). The business had revenue of $291.34 million during the quarter, compared to analyst estimates of $310.96 million. During the same period last year, the business posted ($2.28) earnings per share. The company’s revenue for the quarter was down 18.5% compared to the same quarter last year. On average, analysts forecast that Novavax, Inc. will post -0.82 earnings per share for the current fiscal year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.